An Implementation Tool For US Professionals: First Void Urine Self-Sampling for Primary HPV Cervical Cancer Screening
The national coverage of cervical cancer screening in the US is falling, with about 1 in 4 women not up to date with screening1. Under-screened women bear the greatest burden of disease. Evidence shows 60-64% of American women diagnosed with cervical cancer were unscreened, highlighting the need to explore alternative methods to improve access2-4. In Read More >
Mapping and comparing COPD Care Pathways across 10 countries to understand barriers to optimal care: clinicians’ perspectives
Care Pathway Mapping for Dravet Syndrome (DS) Patients in England
Analysing the COPD care pathway in Japan, Canada, England, and Germany: a global view
A Cost-Effectiveness Analysis of Fenfluramine for the Treatment of Seizures for Patients with Dravet Syndrome (DS) in the UK Setting
Determining the Relationship of Seizures, Seizure Free Days and Other Predictors of Health Related Quality of Life in Patients with Dravet Syndrome (DS) and Their Carers
Evaluating the benefits and costs of using an mRNA versus DNA HR-HPV assay in the National Cervical Screening Programme in the Netherlands
Modelling the impact of using a DNA compared to mRNA HPV assay as part of the cervical screening programmes in Sweden and Denmark
Estimating the costs and benefits of HR-HPV assay choice in a theoretical HPV primary cervical screening algorithm in Ontario, Canada
Evaluating the choice of HPV assay in the French cervical screening programme with a decision tree model
